LETTER TO THE EDITOR: The Effects of Nutraceuticals in Patients with or without Chronic Kidney Disease: Classification Matters

Abstract

We have read with great interest the study by Cicero and colleagues [1], reporting the long-term effects of lipidlowering nutraceuticals on Low Density Lipoprotein Cholesterol (LDL-C) levels and arterial stiffness. The impressive reduction of LDL-C combined with the excellent safety profile points towards further research in this field and calls for a wider use of nutraceuticals in everyday clinical practice. Furthermore, the beneficial effects of nutraceuticals in patients with chronic kidney disease (CKD) are of clinical importance, since this group of patients is highly susceptible to atherosclerosis and cardiovascular disease is their primary cause of death [2-4].